Program
KT-621
A development code.
Its studies are mostly in Dermatitis, Atopic · Asthma, led by Kymera Therapeutics.
Furthest: phase 2, since Oct 13, 20256 company-led studies, 4 open or runningNext primary completion: Apr 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kymera Therapeutics | 64 open or running | phase 2since Oct 13, 2025 | Oct 23, 2024 | Apr 2027phase 1 · NCT07823205 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 23, 2024First study: phase 1 study in Healthy Participants StudyFirst studyNCT06673667 · 118 enrolled · United States
- Apr 9, 2025Phase 1 study in Dermatitis, AtopicNCT06945458 · 22 enrolled · United States
- Oct 13, 2025Phase 2 study in Dermatitis, AtopicNCT07217015 · 200 enrolled · United States, Australia, Canada and more
- Jan 6, 2026Phase 2 study in Pulmonary EosinophiliaNCT07323654 · 264 planned · United States, Argentina, Austria and more
- Jun 24, 2026Phase 2 study in AsthmaNCT07677059 · 264 planned · United States, Germany, Poland and more
- Sep 11, 2026Phase 1 study in Healthy ParticipantsNCT07823205 · 54 planned · United States
Ahead
- Apr 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07823205
- Jun 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07217015
- Dec 2027Primary completion: phase 2 study in Pulmonary EosinophiliaNCT07323654
- Dec 2028Primary completion: phase 2 study in AsthmaNCT07677059
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07823205Healthy Participants · United States | 1 | Recruiting | Apr 2027 | 54 |
| NCT07677059Asthma · United States, Germany, Poland and more | 2 | Recruiting | Dec 2028 | 264 |
| NCT07323654Pulmonary Eosinophilia · United States, Argentina, Austria and more | 2 | Recruiting | Dec 2027 | 264 |
| NCT07217015Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Active, not recruiting | Jun 2027 | 200 |
| NCT06945458Dermatitis, Atopic · United States | 1 | Completed | Nov 10, 2025 | 22 |
| NCT06673667Healthy Participants Study · United States | 1 | Completed | Apr 23, 2025 | 118 |
How it is read
Names in the registry
- “KT-621”, 8 entries
Codes read as this program: KT621.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.